Chronic myeloid leukemia is a type of blood and bone marrow cancer that develops when abnormal white blood cells grow and accumulate. It is commonly associated with a genetic change known as the Philadelphia chromosome. Some people may experience few symptoms initially, while others may notice fatigue, weight changes, night sweats, or abdominal discomfort. Diagnosis involves blood tests, bone marrow examinations, and genetic testing. Modern treatment approaches, particularly targeted therapies, have changed the management of chronic myeloid leukemia and allow many patients to control the disease effectively with regular medical monitoring and individualized care.
Chronic myeloid leukemia, often called CML, is a cancer that affects blood-forming cells in the bone marrow. The disease causes the production of abnormal myeloid cells, which can build up in the blood and other parts of the body. CML is usually associated with the formation of the Philadelphia chromosome, which creates an abnormal gene known as BCR::ABL1. This genetic change produces a protein that encourages leukemia cells to grow. Understanding symptoms, diagnostic methods, and available treatment approaches can help patients and families become more informed about the condition.
CML may develop gradually, and some individuals have no noticeable symptoms when the condition is first identified. In certain cases, it is discovered during routine blood testing. As abnormal blood cells increase, symptoms may become more noticeable. The symptoms can vary depending on the stage of the disease and other individual health factors.
Diagnosis generally begins with a complete blood count to examine the number and types of blood cells. If the results suggest leukemia, additional testing may be recommended. A bone marrow aspiration or biopsy can provide information about blood-forming cells within the bone marrow.
Genetic and molecular tests are also important because they can identify the BCR::ABL1 gene fusion associated with most cases of CML. These tests can also help healthcare professionals monitor how the disease responds to treatment over time.
Treatment for chronic myeloid leukemia has changed significantly with the development of targeted medicines. A major group of treatments includes tyrosine kinase inhibitors, often called TKIs. These medicines are designed to block signals produced by the abnormal BCR::ABL1 protein and reduce the growth of leukemia cells.
CML is generally managed through long-term medical follow-up. Regular monitoring allows healthcare professionals to evaluate treatment response and identify changes that may require attention. Treatment decisions depend on factors such as the phase of CML, genetic findings, previous treatment response, possible side effects, and a person's overall health. Ongoing research continues to examine new approaches that may further improve disease management and long-term outcomes.